AGOURA HILLS, Calif. and SANTA CLARA, Calif. , Aug. 19, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) and PointR Data Inc. (PointR), a privately-held, developer of high performance cluster computer and artificial intelligence company, announced today that they have
AGOURA HILLS, Calif. , July 30, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative treatments for cancer, announced today that its team members will participate and provide clinical
AGOURA HILLS, Calif. , July 16, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic"), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to development of innovative treatments for cancer, announced today that Dr. John H. Sampson , an internationally recognized
AGOURA HILLS, Calif. , June 12, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB: MATN) dedicated to development of innovative treatments for cancer announced today that four internationally recognized clinical scholars have joined
-Relocation of Corporate Headquarters -Introduction of Amit Shah as incoming CFO -Presentation of Integrated Pipeline at BIO2019 AGOURA HILLS, Calif. , June 10, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN), a biopharmaceutical company developing investigational drugs for
SOUTH SAN FRANCISCO, Calif. , May 15, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, announced today financial results for the first quarter of 2019.
-Merger creates a publicly-traded clinical stage immuno-oncology company developing treatments for advanced cancers including aggressive brain tumors, pancreatic cancer, and melanoma -Phase 2 clinical data on lead product candidate OT-101 demonstrated robust tumor responses including complete
Forms Late Clinical-Stage Cancer Immunotherapy Company Focusing on TGF-β RNA Therapeutics SOUTH SAN FRANCISCO, Calif. and AGOURA HILLS, Calif. , April 18, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) and Oncotelic Inc. , a privately-held, late clinical-stage cancer immunotherapy
SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced third quarter 2018 financial results. For the three months ended
SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing drugs for the treatment of orphan oncology indications, today announced it will provide an overview of the company and its programs at the 20 th Annual
